Jones Trading Upgrades Beam Therapeutics (BEAM)

Fintel reports that on March 10, 2025, Jones Trading upgraded their outlook for Beam Therapeutics (NasdaqGS:BEAM) from Hold to Buy.

Analyst Price Forecast Suggests 92.72% Upside

As of March 4, 2025, the average one-year price target for Beam Therapeutics is $49.51/share. The forecasts range from a low of $25.25 to a high of $84.00. The average price target represents an increase of 92.72% from its latest reported closing price of $25.69 / share.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Beam Therapeutics is 30MM, a decrease of 52.90%. The projected annual non-GAAP EPS is -5.25.

What is the Fund Sentiment?

There are 472 funds or institutions reporting positions in Beam Therapeutics. This is unchanged over the last quarter. Average portfolio weight of all funds dedicated to BEAM is 0.37%, an increase of 8.68%. Total shares owned by institutions increased in the last three months by 0.90% to 94,105K shares. The put/call ratio of BEAM is 0.55, indicating a bullish outlook.

What are Other Shareholders Doing?

Farallon Capital Management holds 8,239K shares representing 10.16% ownership of the company. In its prior filing, the firm reported owning 8,208K shares , representing an increase of 0.38%. The firm increased its portfolio allocation in BEAM by 5.31% over the last quarter.

ARK Investment Management holds 7,068K shares representing 8.71% ownership of the company. In its prior filing, the firm reported owning 6,531K shares , representing an increase of 7.60%. The firm decreased its portfolio allocation in BEAM by 0.25% over the last quarter.

Arch Venture holds 4,540K shares representing 5.60% ownership of the company. In its prior filing, the firm reported owning 4,835K shares , representing a decrease of 6.49%. The firm increased its portfolio allocation in BEAM by 7.59% over the last quarter.

ARKK - ARK Innovation ETF holds 4,410K shares representing 5.44% ownership of the company. In its prior filing, the firm reported owning 4,929K shares , representing a decrease of 11.77%. The firm decreased its portfolio allocation in BEAM by 32.11% over the last quarter.

Nikko Asset Management Americas holds 3,958K shares representing 4.88% ownership of the company. In its prior filing, the firm reported owning 3,553K shares , representing an increase of 10.23%. The firm increased its portfolio allocation in BEAM by 7.83% over the last quarter.

Beam Therapeutics Background Information
(This description is provided by the company.)

Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam's suite of gene editing technologies is anchored by base editing, a proprietary technology that enables precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

Click to Learn More

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.